TRIM3 Antibody (OAAF02050)
- Known as:
- TRIM3 Antibody (OAAF02050)
- Catalog number:
- oaaf02050
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- Aviva Systems Biology
- Gene target:
- TRIM3 Antibody (OAAF02050)
Related genes to: TRIM3 Antibody (OAAF02050)
- Gene:
- TRIM3 NIH gene
- Name:
- tripartite motif containing 3
- Previous symbol:
- RNF22
- Synonyms:
- HAC1, BERP, RNF97
- Chromosome:
- 11p15.4
- Locus Type:
- gene with protein product
- Date approved:
- 2000-07-31
- Date modifiied:
- 2016-10-05
Related products to: TRIM3 Antibody (OAAF02050)
Related articles to: TRIM3 Antibody (OAAF02050)
- Genome reduction is widely used to improve microbial bioprocessing hosts by reducing the burden of inessential physiology. Rationally identifying genomic regions that are dispensable or even detrimental to bioprocessing is challenged by our inability to map genome sequence to function across complex regulation and physiology. Thus, there is a need for tools that rapidly generate reduced genome strains with improved performance in process-relevant conditions. Here, we report a Cascade-Cas3-enabled method called TRIM3 that generates large deletions by targeting a randomly integrated transposon, enabling facile generation of a genome-reduced mutant library. Mutants with improved performance were isolated following growth-coupled selection and analyzed by long-read DNA sequencing to identify deletions in their genomes. We deploy this system iteratively in the industrial host Cupriavidus necator H16 on fructose and on formate. After two rounds of TRIM3, we isolate a strain containing a total reduction of 1.4 Mb (18.4% of the genome) that grows 25% faster in a bioreactor on fructose and a strain with a total reduction of 0.5 Mb (7.3% of the genome) that grows 14% faster on formate. This work demonstrates a method for random, iterative, growth-selectable genome reduction that represents a new avenue for large-scale genome modifications and the development of improved bioprocessing hosts. - Source: PubMed
Fulk Emily MSwart Reuben MNakamura Akira KQuinto Laura BSànchez I Nogué VioletaCalvey Christopher HTharun IndulekhaIsaacs Farren JJohnson Christopher W - - Source: PubMed
Publication date: 2026/07/12
Rahouma Mohamed - Pediatric T-cell acute lymphoblastic leukemia (T-ALL) remains a therapeutic challenge, with approximately 20% of patients experiencing relapse due to a limited understanding of molecular drivers [...]. - Source: PubMed
Publication date: 2026/04/22
Sun YuXu YuhaoLu Chao - TRIM-NHL proteins, a subfamily of Tripartite Motif (TRIM) family proteins, are characterized by the presence of NHL structures in their C-terminal domains. In humans, this subfamily mainly includes TRIM2, TRIM3, TRIM32, TRIM71, and the recently discovered TRIM56 protein. The C-terminal domains of these five proteins exhibit varying degrees of difference. Increasing evidence indicates that TRIM proteins are involved in numerous physiological and pathological processes related to life and health, and TRIM71 is no exception. In this article, we introduce the functional and structural characteristics of TRIM family proteins. We mainly discuss the known functions and related specific structures of the TRIM71 protein in the TRIM-NHL subfamily, as well as the exploration of its druggability. We also summarize and organize its physiological functions and biological processes in disease regulation. - Source: PubMed
Publication date: 2026/05/12
Gan Qi-FengHan Zi-XvZheng Zu-Guo - Our objective was to investigate TRIM3 expression and its role in the immune microenvironment of non-small-cell lung cancer (NSCLC). - Source: PubMed
Publication date: 2026/03/23
Jiang WenfaChen Shuchen